Piper Sandler Reiterates Overweight on DexCom, Raises Price Target to $95

Benzinga Newsdesk www.benzinga.com Positive 57.6%

Neg 0% Neu 0% Pos 57.6%

Piper Sandler analyst Matt O'Brien reiterates DexCom (NASDAQ:DXCM) with a Overweight and raises the price target from $88 to $95.